INTRODUCTION
The use of monoclonal antibodies produced by the hybridoma technique developed in 1975 by Kohler and Milstein [1] has led to a revolution in the biological sciences. Monoclonal antibodies, unlike conventional antibodies, are directed against a single antigenic determinant. Their unique specificity allows diverse studies, which were previously difficult or impossible, to be done. These studies range from the selective isolation and characterization of virtually any biological substance to the functional analysis of such substances [2] . In the future, monoclonal antibodies directed against unique tumor antigens promise a radical development in cancer chemotherapy.
It is now rare to find an investigator who does not or could not use monoclonal antibodies in some aspect of his research. Because of this demand for monoclonal antibodies, many companies have recently begun selling such reagents and some universities have set up "hybridoma facilities" in which investigators can have hybridomas custom-made. However, the desired antibody may not be on the market or a hybridoma facility may not be available, in which case it is most convenient to produce one's own monoclonal antibodies.
Descriptions of the process for making hybridomas are available [3, 4] , but the purpose of this guide is to provide complete step-by-step instructions for the production of monoclonal antibodies using the hybridoma technology. Its use requires a minimal degree of laboratory experience, including tissue culture experience, while its content leaves few questions unanswered.
The basic process of making monoclonal antibodies is simple-a mouse is immunized with the appropriate antigen, spleen cells from the immunized animal, many of which are producing antibody, are fused with murine myeloma cells using 387 polyethylene glycol, antibody from the resultant hybridomas secreted into the culture medium screened for the activity of interest, and a permanent source of the desired antibody is established (Fig. 1) .
The general format of fusing mouse spleen and myeloma cells together has now been expanded successfully to include fusions of primed rat spleen cells with mouse or rat myeloma cells [5, 6] . While there is an obvious desire to have human monoclonal antibodies, fusions of human peripheral blood cells with mouse myeloma cells rarely yield hybrids with a stable number of human chromosomes. To solve this problem, one group of investigators has developed a human myeloma line which has made it possible to make humani x human hybridomas [7] . The techniques described in this paper are generally applicable to the above situations with the exception that the culture media requirements for particular myeloma lines may vary.
It should be noted that there are two additional methods of producing monoclonal antibodies by non-standard hybridoma processes. The first, described by Wright [8] , uses diethyl pyrocarbonate to irreversibly inactivate sulphurcontaining enzymes in a given myeloma cell line. The damaged tumor cells are then fused in a conventional manner with primed B cells and the active enzymes of the B cells salvage the tumor cell to yield a functional hybridoma. The second method uses the well-established technique of transforming human B cells with Epstein-Barr virus and then selecting the transformed lines which secrete the antibody of interest [9] .
A word of caution: The production of hybridomas requires many months of diligent effort. Most important, a simple and reliable screening assay to examine the numerous culture supernatants for the desired antibody must be available before cell fusion. The successful development of uniquely specific monoclonal antibodies is well worth the effort. PREPARATION [10] . The selective system we work with revolves around the enzyme hypozanthineguanine-phosphoribosyl transferase, HGPRT. This enzyme is responsible for the purine salvage pathway in mammalian cells. These cells are also capable of synthesizing purines de novo. Under most conditions both pathways probably operate to a certain extent. If a cell lacks HGPRT, the salvage pathway is blocked and purines must be manufactured from non-purine materials.
8-azaguanine is an antimetabolite which "looks enough" like the purine guanine to enter some of the normal salvage pathways of guanine. 8-azaguanine is then incorporated into DNA, interfering with normal cell growth and leading to cell death. Since 8-azaguanine must be "salvaged" and HGPRT is responsible for the salvage pathway, any cell which lacks HGPRT activity cannot utilize 8-azaguanine and will grow in its presence.
A selective system which operates on the same enzyme but in the opposite sense Fetal calf serum which has been screened for supporting the growth of hybrids is used for the initial stages of hybridoma culture. "Bobby calf" or calf serum, which is much less expensive than fetal calf serum, is used for hybrids beyond the 10 ml culture stage and for the maintenance of SP 2 cells.
Concentrations
The concentrations of HAT are from Littlefield's original paper with the exception that we use 2 x aminopterin. The calculated final molarities of these reagents and 8-azaguanine have been made assuming that an aliquot of the particular chemical is placed in a total volume of 500 ml -a slightly incorrect assumption as the additives (serum, etc.) result in a final volume greater than 500 ml. Store at room temperature in 1 ml aliquots (it will become quite alkaline). Medium for SP 2 500 ml RPMI 1640 5 ml HEPES 5 ml L-glutamine 50 ml serum 10 ml pen-strep 1 ml azaguanine Grow in 5% CO2. Do not let cell density exceed 7 x 105 cells/ml.* HT Medium 500 ml DMEM 5 ml HEPES 5 ml L-glutamine 5 ml sodium pyruvate 5 ml HT 50 ml NCTC 109 100 ml fetal calf serum 5 ml antibiotic-antimycotic Grow in 8% C02.
Beggar's Medium (for stable hybrids) 500 ml RPMI 1640 5 ml HEPES 5 ml L-glutamine 50 ml serum 10 ml pen-strep Grow in 5%0 C02. HA T Medium 500 ml DMEM 5 ml HEPES 5 ml L-glutamine 5 ml sodium pyruvate 5 ml HT 50 ml NCTC 109 100 ml fetal calf serum 5 ml antibiotic-antimycotic 0.5 ml aminopterin Grow in 8%o CO2. FUSION The actual act of fusing myeloma and spleen cells takes only minutes. While these minutes are indeed crucial to the success of making hybridomas, planning for the fusion and maintenance of the hybrids requires the utmost diligence.
*If the cells are grown in flasks, an estimate of cell density can be made by viewing the flask on an inverted microscope: when the cells are nearly adjacent to one another, the cell density is about 5 x 105 cells/ml, and they should be split. Splitting is done most simply by taking 0.5 ml from the mature cultures and adding to 10 ml of new medium, i.e., 1:20 split. saturated copper sulfate to serve as a barrier to contamination. Two drops from these 5 ml pipettes delivers about 0.12 ml, which is why this odd figure is used in step 11 rather than 0.1 ml. For every microtiter plate in which the inner 60 wells are used, 7.2 ml of medium can be added, assuming two drops/well (Fig. 3) .
Maintaining Newly Fused Cells 1. Call the day of the fusion day 0. 2. On day 1, add one drop of HAT medium to each well. 3. On day 4, aspirate half of the supernatants from each well (a flamed six-inch Pasteur pipette attached to an aspirator works well) and replace with 2 drops of HAT medium. 4. Repeat step 3 on day 7. 5. After day 7, fusomas may be fed HT medium on a regular basis, every three to five days. 6. Clones should appear macroscopically between 10 to 20 days (Fig. 4) present in the target population, then I2'l-rabbit anti-mouse Ig should be used instead of protein A so that all mouse antibody classes will be detected. The second assay is a complement-dependent cytotoxicity assay in which cells are incubated with hybridoma culture fluid followed by a source of rabbit complement, which leads to cell lysis as a readout of positive activity. This assay has the advantage over the first one in that clones secreting IgM antibodies, which are almost invariably cytotoxic, are detected but the assay is more tedious.
The third assay is a solid-phase sandwich radioimmunoassay which can be used to detect antibodies to virtually any nominal antigen. The CLONING AND EXPANSION OF HYBRIDOMAS Once it has been determined which wells of the original master microtiter plates contain hybridomas of potential interest, it is imperative that the cells from these wells be (1) expanded to 1 ml cultures and (2) subcloned immediately. The reasons are manyfold: (1) expansion will place the hybrids in multiple places insuring against the potential loss secondary to contamination and other accidents, (2) the hybrids are very unstable at this juncture so that the appearance of one colony of cells does not necessarily mean that all of the cells are producing antibody and non-producers could easily overgrow the producers, and (3) multiple activities could be present in a single well and cloning is necessary to examine this possibility.
A "feeder" layer is used at this early stage of expansion and cloning. BALB/c thymocytes are sufficient feeders for any fusion because the myeloma line SP 2/0 is derived from a BALB/c hybridoma. There are only two occasions when a feeder layer is necessary. One is in the actual cloning process by limiting dilution or solid agar (the latter is easier); the other, when the 0.2 ml master well is expanded to 1 ml culture. Expansion of the subclones from limiting dilution or agar cloning does not require feeder cells nor does expansion from 1 ml to a 10 ml culture.
In the sections which follow, "HT" medium is often used. It should be noted that hypoxanthine and thymidine are not necessary for the growth of hybrids by this time and that it is simpler to add HT to the media to avoid any confusion that may arise between improperly labeled bottles. 4 . Aliquot into 1 ml multiwells. 5 . Transfer the entire contents of the 0.2 ml master well to the 1 ml culture. 6. Remove 0.2 ml from the 1 ml culture and replace in the master well. (This procedure is a safeguard in the rare event the 1 ml culture fails to grow.) 7. Three to six days later cells will cover the multiwell and media will be yellow. It should be tested for activity. 8. If it is still active, expand this uncloned colony to a 10 ml flask.
9. Supernatant from the 10 ml flask should be saved and the cells frozen in the evient the concurrent cloning procedure fails and must be repeated.
CLONING ON 
DIFFICULTIES IN THE PRODUCTION OF HYBRIDOMAS
It should be apparent from reading this guide that tedious work is a requirement for the successful production of monoclonal antibodies. In addition, there are three major difficulties associated with making hybridomas. First, as with any tissue culture technique, the fear of infection is ever present. Antibiotics combined with good sterile technique are usually successful at preventing bacterial contamination. Molds are more difficult to prevent. Antimycotics are usually successful at delaying but not preventing this kind of contamination. Contaminated wells appear most commonly in the outer wells of the microtiter plates which suggests spread from the incubator, and it is for this reason that the outermost wells of the plate should not contain medium. If a plate is found to have contaminated wells, it is usually best to 401 discard the plate. If there is a pressing reason to maintain the particular plate, the contents of as many wells as possible should be replaced with a saturated copper sulfate solution.
The second problem concerns the sluggish growth or lack of growth of visible clones after a fusion. How is it possible that healthy-appearing tumor cells cease dividing? A clear answer is not available but presumably various factors produced by cells in the original spleen cell population have the ability to suppress hybridoma growth. Transferring the cells to a new microtiter plate usually solves this problem as the suppressive cells appear to be left behind in the master well. An extension of this problem concerns the slow or unsuccessful growth of cells after splitting or changing from HT to Beggar's medium. If cells are split in too dilute a fashion, growth can generally be salvaged by centrifugation of the cells and resuspension in a smaller volume of medium. Sometimes a cell line will begin to die when transferred from HT to Beggar's medium. In this case it is necessary to place the cells into HT medium again for a few days and test to see if the cells that grow out are capable of being sustained in Beggar's-they usually do well the second time.
The third problem is the loss of antibody production by hybridomas. This phenomenon is common in the early stages of growth as cell hybrids have a tendency to lose chromosomes. Often 50 percent of the original positive wells will be lost. Early cloning is essential to obtain relatively stable hybrids and it is not unreasonable to suggest that a particular line be subcloned three times before it is considered stable.
